Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
617 Leser
Artikel bewerten:
(2)

Uppsala University Hospital First in Sweden to Treat Patient With Elekta Unity Cancer Treatment System

UPPSALA, Sweden, Nov. 14, 2019 /PRNewswire/ -- Sweden's first-ever patient to be treated on the groundbreaking Elekta Unity MR-Linac radiation therapy system took place at Uppsala University Hospital yesterday. Elekta Unity gives doctors the "vision" to zero in on tumors and avoid healthy tissues and thereby addresses an unmet need in cancer therapy - it enables clinicians to confidently see and track the target during treatment and respond accordingly, personalizing therapy for each patient every time they are treated. With Elekta Unity, radiation therapy can be more effective, which could mean not only fewer treatment-related side effects, but also the potential for fewer treatment sessions and visits to the hospital by the patient.

Zahra Taheri-Kadkhoda, Head of Radiation Treatment at Uppsala University Hospital, said: "An important advantage of radiation therapy guided by MR images is that the treatment becomes more individualized and can be targeted more precisely to the tumors. This can increase the chance of better tumor control and less risk of damage to surrounding healthy tissue, especially for tumor sites which are hard to visualize with non-MR techniques. The MR-Linac is also an inspiring project for broad and open collaborations between different medical disciplines and technical professionals with an ultimate goal to improve patient care."

Elekta President and CEO, Richard Hausmann, said: "We are very excited that Uppsala University Hospital, as the first clinic in Sweden, has joined the growing number of cancer clinics around the world providing precision radiation medicine to their patients using the most advanced technology. Both Elekta and Uppsala University Hospital are renowned for their innovative approach to providing advanced cancer care. These synergies will benefit many of the more than 60,000 people diagnosed with cancer in Sweden each year."

To date, there are 18 Elekta Unity systems in operation globally, of which eight are in Europe. The new technology integrates two critical but distinct technologies in a single platform: a state-of-the-art, high field MR imaging system, and a next-generation Elekta (EKTA-B.ST) linear accelerator. Tumors and surrounding organs can be located and their movement accurately tracked at the time of treatment. This allows treatment plans to be adapted while the patient is on the table in response to changes in tumor position, shape, biology and the relationship to sensitive organs over time.

Elekta Unity will be used to treat a wide range of cancers and may enable new therapeutic options for hard-to-treat cancers with anatomies that require crystal-clear imaging to effectively distinguish the tumor from nearby healthy tissues and organs-at-risk. This will allow anatomical structures that previously were determined unsuited for radiotherapy to be considered for treatment.

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

About Uppsala University Hospital
Uppsala University Hospital is one of Sweden's largest hospitals, offering medical and nursing care of the highest standard. It is a source of both unique medical knowledge and the most advanced care available. Each year, more than 700,000 people are cared for. Uppsala University Hospital is a full-scale university hospital with 8,000 employees and 1,000 beds.

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Public Affairs
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: raven.canzeri@elekta.com
Time zone: ET: Eastern Time

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elekta/r/uppsala-university-hospital-first-in-sweden-to-treat-patient-with-elekta-unity-cancer-treatment-syst,c2960758

The following files are available for download:

https://mb.cision.com/Main/35/2960758/1140736.pdf

Release

https://news.cision.com/elekta/i/elekta-unity-full-room-side-view-image,c2715432

Elekta Unity Full Room Side View Image

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.